Zusammenfassung
Mit der Arbeit von Csernansky et al. (9) liegt eine methodisch hochwertige Langzeitstudie vor, die einen wissenschaftlich exakten Vergleich der rezidivprophylaktischen Eigenschaften eines konventionellen Neuroleptikums und eines Atypikums ermöglicht. Auch Patienten, welche vermeintlich stabil auf ein konventionelles Neuroleptikum eingestellt sind, können von einer Umstellung auf Risperidon profitieren. Bis zum Vorliegen weiterer Studienergebnisse kann der therapeutische Einsatz von Risperidon in der Langzeittherapie von chronischen Schizophreniepatienten gut empfohlen werden.
Summary
The study of Csernansky et al. (9) reports one of the first adequately designed and analysed trials to demonstrate the efficacy of the atypical neuroleptic drug risperidone in the maintenance treatment of schizophrenia in comparison to the conventional antipsychotic drug haloperidol. Adult outpatients with clinically stable schizophrenia and conventional antipsychotic treatment can benefit from a switch to risperidone. Until new data is published the use of risperidone as a first-line treatment for patients with schizophrenia is recommended to induce remission and to prevent relapse.
Key Words
Schizophrenia - prevention - relapse - risperidone - haloperidol
Literatur
-
1
Cannon M, Jones P.
Schizophrenia.
J Neurol Neurosurg Psychiatry.
1996;
60
604-613
-
2
Leitlinien der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN).
AWMF-Leitlinien-Register Nr. 038/009.
-
3
Daniel DG. et al. .
Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia.
The Sertindole Study Group.
Psychopharmacol Bull.
1998;
34
61-69
-
4
Speller JC. et al. .
One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms.
Amisulpride v. Haloperidol.
Br J Psychiatry.
1997;
171
564-568
-
5
Essock SM. et al. .
Clozapine's effectiveness for patients in state hospital results from a randomized trial.
Psychopharmacol Bull.
1996;
32
683-697
-
6
Tran PV. et al. .
Oral olanzapine versus oral haloperidole in the maintenance treatment of schizophrenia and related psychosis.
Br J Psychiatry.
1998;
172
499-505
-
7
Hirsch SR. et al. .
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
J Clin Psychiatry.
2002;
63
516-523
-
8
Glick ID, Berg PH.
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Int Clin Psychopharmacol.
2002;
17
65-68
-
9
Csernansky JG. et al. .
A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with Schizophrenia.
N Eng J Med.
2002;
346
16-22
-
10
Geddes J.
Prevention of Relapse in Schizophrenia.
N Eng J Med.
2002;
346
56-58
-
11
Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL.
The functional significance of symptomatology and cognitive function in schizophrenia.
Schizophrenia Research.
1997;
25
21-31
Korrespondenzadresse:
PD Dr. Hans-Peter Volz
Krankenhaus für Psychiatrie und Psychotherapie Schloss Werneck
Balthasar-Neumann-Platz 1
97470 Werneck
